R&D News | pharmaphorum

News

Roche bounces back in PIK3 with inavolisib data

A few years ago, Roche abandoned the development of its lead PIK3CA-targeting drug taselisib on safety grounds, allowing rival Novartis to beat it to market, but now it ha

News

Alto hits a high note with AI-driven depression therapy

Alto Neuroscience has said its therapeutic approach to depression of matching patients to drugs based on brain biomarkers has shown promise in a phase 2a trial.

News

Seismic shakes up $121m for AI-designed immunology drugs

Seismic Therapeutics has raised $121 million in second-round financing that will be used to take its two lead drugs through early-stage clinical testing.

News

Merck grabs late-stage oncology drug from China’s Abbisko

Germany’s Merck KGaA is paying Chinese biotech Abbisko Therapeutics $70 million upfront for rights to a drug in phase 3 testing for tenosynovial giant cell tumour (TGCT), a rare disea

News

Pfizer drops twice-daily obesity therapy due to side effects

Pfizer has decided to discontinue the development of another of its experimental obesity therapies, after seeing high rates of discontinuation with the drug in a mid-stage

News

Roche makes obesity play with $2.7bn deal to buy Carmot

Roche has agreed a deal to acquire US biotech Carmot Therapeutics that, if consummated, will thrust it into the increasingly competitive market for incretin-based therapie

Roche bounces back in PIK3 with inavolisib data

Alto hits a high note with AI-driven depression therapy

Seismic shakes up $121m for AI-designed immunology drugs

Merck grabs late-stage oncology drug from China’s Abbisko

Pfizer drops twice-daily obesity therapy due to side effects

Roche makes obesity play with $2.7bn deal to buy Carmot

UK backs start-up Potential Sciences' AI-powered drug hunt

Discover a new era of healthcare panel engagement: Grounded ...

News

Editor's Picks